Chemotherapy/Radiation

Phase 3Small molecule

Chemotherapy/Radiation is one of 15 small molecule programs targeting Hepatocellular Carcinoma (HCC). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatocellular Carcinoma (HCC)Recruiting

Hepatocellular Carcinoma (HCC)Phase 3

Recruiting

Competition

Competitive Landscape

17 competitors in Hepatocellular Carcinoma (HCC)

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 2

3 2

Yervoy

Bristol-Myers Squibb

Phase 2

2 3

Tecentriq

Roche

Phase 2

2 4

Imfinzi

AstraZeneca

Phase 2

1 5

Opdivo

Bristol-Myers Squibb

Phase 2

1 6

Farxiga

AstraZeneca

Phase 2

1 7

Beyfortus

BeiGene

Phase 2

1 8

Zofran

Novartis

Phase 2

1 9

Nitrostat

VViatris Specialty LLC

Phase 2

1 10

Actemra

CCelltrion

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Recruiting

Hepatocellular Carcinoma (HCC)

NCT07027436

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma (HCC)1 trial

Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma. A Randomized Window of Opportunity Trial (DARTS)

Recruiting·HHamilton Health Sciences Corporation·Phase 3·NCT07027436·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Chemotherapy/Radiation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Chemotherapy/Radiation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Chemotherapy/Radiation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hamilton Health Sciences Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHamilton Health Sciences Corporation

Chemotherapy/Radiation

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Hepatocellular Carcinoma (HCC)1 trial

References

Drug Info

Quick Facts

Related News